Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIA randomized open-label trial of Dalotuzumab plus irinotecan versus cetuximab plus irinotecan in metastatic rectal cancer with high IGF-1/low IGF-2
KCT0000497Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalotuzumab, cetuximab, irinotecan in rectal cancer, sponsored by Merck & Co.. Planned start Aug 2012; status: not yet recruiting.
02
Drugs
dalotuzumabcetuximabirinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on KCT0000497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000497.